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Context: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy 
currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. 
Certolizumab pegol is the ﬁ  rst PEGylated biologic anti-TNF agent and has a high binding afﬁ  nity 
for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment 
Evaluation in Crohn’s Disease Safety and Efﬁ  cacy) 2 trial of certolizumab pegol in patients 
with Crohn’s disease.
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Q.   How would you describe the role of anti-TNFs 
in Crohn’s disease?
A.     Currently, anti-tumor necrosis factors (TNFs) are reserved for the treatment of 
patients with moderate-to-severe Crohn’s disease for whom standard therapy 
(with immunomodulators, for instance) has failed. The role of anti-TNF agents, 
however, is evolving. During the past few years we have seen the introduction 
of a ‘top-down’ treatment strategy, which involves immunomodulators and 
biologic agents being used earlier in the course of the disease in order to prevent 
some of the complications that arise with Crohn’s disease. Consequently, we 
are starting to use anti-TNF therapy earlier for patients with Crohn’s disease 
who have features of more aggressive disease, such as a history of surgery, 
ﬁ  stulas, or the need for steroids at the initial presentation. Such a strategy 
more effectively improves quality of life and changes the natural course of 
the disease. For instance, in perianal Crohn’s disease, an anti-TNF is now the 
ﬁ  rst-line therapy for our patients. We use an anti-TNF quite frequently at ﬁ  rst 
diagnosis in order to prevent some of the complications that can occur with 
ﬁ  stulizing Crohn’s disease.
Q.   What do you think certolizumab pegol brings 
to the equation?
A.      Certolizumab pegol brings a novel option for patients who are suitable can-
didates for anti-TNF therapy and those who may have had difﬁ  culties with 
the conventional anti-TNFs that are currently available. It also gives patients 
perhaps a more convenient option in that it only needs to be administered once 
monthly, as opposed to weekly or every other week with the other injectable 
agents available. Certolizumab pegol has an increased drug half-life as a result Biologics: Targets & Therapy 2008:2(1) 126
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of it being PEGylated (ie, conjugated to polyethylene 
glycol) and this makes less frequent dosing possible. 
The efﬁ  cacy and tolerability data of certolizumab 
pegol look very good and I am hopeful that it will 
provide a very effective treatment option for patients 
with Crohn’s disease.
Q.   Now could you describe the 
methodology of the PRECiSE 2 
clinical trial?
A.      PRECiSE 2 is a multicenter, randomized, double-
blind, placebo-controlled trial. It included 668 patients 
with moderate-to-severe Crohn’s disease. To be 
enrolled in this trial, patients had to have a Crohn’s 
Disease Activity Index (CDAI) score of 220 points. 
Patients were given open-label certolizumab pegol 
400 mg at 0, 2, and 4 weeks (induction). Those who 
achieved a 100-point decrease in their CDAI score 
were then randomized to receive either placebo 
every 4 weeks or certolizumab pegol 400 mg every 
4 weeks (maintenance). The primary endpoint was 
the number of patients with a baseline C-reactive 
protein (CRP) concentration 10 mg/L who had a 
100-point decrease in CDAI score at Week 26. Data 
for the certolizumab pegol group were compared with 
those for the placebo group.
Q.   What were the main ﬁ  ndings 
from the PRECiSE 2 trial?
A.     The primary endpoint was a 100-point response on the 
CDAI. We found that 63% of patients who received 
certolizumab pegol met that endpoint, compared with 
36% of patients receiving placebo. Another endpoint 
was remission; at Week 26, 48% of patients who 
received certolizumab pegol were in remission com-
pared with 29% of patients in the placebo group. For 
both of these endpoints, the difference was statistically 
signiﬁ  cant. Interestingly, similar results were obtained 
in the overall population, which also included those 
patients who did not have a baseline CRP serum level 
of at least 10 mg/L.
Q.   How do these results compare 
to those of the other anti-TNF 
agents?
A.      It is hard to directly compare the results of one trial 
with the results of another because the trial designs are 
subtly different, and different inclusion and exclusion 
criteria are used. That being said, the endpoints used 
in the different trials are very similar. In PRECiSE 
2 (the remission rate at Week 26 in the certolizumab 
pegol group was 31%. The adalimumab CHARM 
trial was of a similar design to PRECiSE 2, includ-
ing an induction phase followed by a maintenance 
phase) and the remission rate at Week 26 was 27% 
in the active treatment group. In the ACCENT 1 trial 
of inﬂ  iximab, the remission rate in the active group 
was 23% at Week 30.
Q.   In the PRECiSE 2 trial, what was 
the efﬁ  cacy of certolizumab pegol 
in patients with prior exposure 
to inﬂ  iximab?
A.      Many of the trials with biologic anti-TNF agents 
indicate that patients with previous exposure to an 
anti-TNF antibody treatment may have a slightly 
reduced response rate when treated with a second anti-
TNF agent. If you look at those patients in PRECiSE 
2 with no prior inﬂ  iximab exposure, 69% of patients 
who subsequently received certolizumab pegol 
responded, compared with only 40% of the patients 
who received placebo maintenance treatment. Among 
patients who had previously received inﬂ  iximab, the 
corresponding values were 44% of patients receiving 
certolizumab pegol compared with 25% for placebo. 
It may be the case that, over time, the patients with 
prior inﬂ  iximab exposure may develop strictures or 
other such complications that are a bit more refrac-
tory to treatment. This is possibly one explanation 
for the slightly lower response rate in patients who 
have previously received inﬂ  iximab. The response 
rate was still statistically signiﬁ  cantly greater with 
certolizumab pegol than with placebo, but slightly 
lower than in patients for whom certolizumab pegol 
was the ﬁ  rst-line anti-TNF. This observation is not 
speciﬁ  c for certolizumab pegol (having also been seen 
with other anti-TNFs).
Q.   How effective is certolizumab pegol 
in patients who have been recently 
diagnosed with Crohn’s disease?
A.      In PRECiSE 2, we found that when certolizumab 
pegol is used earlier in the disease it tends to be 
more effective. Particularly high response rates were Biologics: Targets & Therapy 2008:2(1) 127
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observed for patients who had had Crohn’s disease for 
less than 1 year; at Week 26, the response rate was 
90% for certolizumab pegol and 37% for placebo. 
Nine out of 10 patients were in response at 6 months, 
and approximately 7 out of 10 were in remission. The 
results were still good among patients who had had 
Crohn’s disease longer, but the rates drop off a little 
bit as the disease duration increases. Those patients 
having Crohn’s disease for between 1 and 5 years 
had a response rate of 57% in the certolizumab pegol 
group compared with 37% in the placebo group. The 
corresponding remission rates were 44% and 24%, 
respectively. So again, this probably reﬂ  ects the fact 
that patients are developing complications of Crohn’s 
disease over time (such as strictures or penetrating 
disease) that are more refractory to treatment. It is 
evidence such as this that supports earlier interven-
tion with biologic agents to prevent progression of 
the disease to more complicated disease states that 
are refractory to treatment.
Q.   Now, moving on, what 
is the tolerability of certolizumab 
pegol?
A.      Most patients tolerate certolizumab pegol very well. 
When you look at the data from clinical trials, there 
are few side effects of the medication. In PRECiSE 
2, the adverse effects that occurred slightly more 
with certolizumab pegol than with placebo included 
headaches, upper respiratory infections, and cough. 
Injection-site reactions or pain were both low (less 
than 3%) in the certolizumab pegol group.
Q.   Do you consider certolizumab pegol 
to be a safe drug?
A.     Certainly. Obviously, all medicines that suppress the 
immune system do have some risk associated with 
them (particularly the risk of infection). However, 
when you look at the PRECiSE 2 trial, for instance, 
the rate of serious adverse events with certolizumab 
pegol was approximately the same as that for placebo. 
The rate of serious adverse events in placebo-treated 
patients was approximately 7%; the rate with certoli-
zumab pegol was approximately 6%. Breaking these 
rates down into the type of serious adverse event 
shows that there was a slightly higher risk of serious 
infections in those patients treated with certolizumab 
pegol (approximately 3%) compared with placebo 
(1%). Reassuringly, at least in the PRECiSE 2 trial, 
there was no evidence of malignancy. Other effects 
that can be a cause for concern in patients who receive 
anti-TNF therapy, including the development of anti-
double-stranded DNA or anti-nuclear antibodies and 
serum sickness-like reactions, occurred with very low 
frequency and at levels similar to placebo in PRECiSE 
2. It should be noted, however, that a single trial is not 
powered to detect uncommon and rare events such 
as opportunistic infection, malignancy, lupus-like 
reactions, and MS-like reactions.
Q.   What is your personal experience 
with this new anti-TNF drug?
A.      At our center, we have enrolled a number of patients 
into the PRECiSE trials. Obviously, we do not know 
who has received placebo and who has received 
certolizumab pegol in the blinded phase of the trials. 
In addition, some of our patients have been receiv-
ing open-label certolizumab pegol for 2.5–3 years 
and most are continuing to do quite well. I am very 
pleased with how well certolizumab pegol works for 
our patients and look forward to seeing it become 
available outside of clinical trials (hopefully in the 
near future).
Q.   Finally, how do you foresee 
the treatment of Crohn’s disease 
in the coming years?
A.    I think we are going to see an increasing use of 
biologic agents earlier in the course of the disease in 
order to prevent some of the complications I men-
tioned earlier: strictures, ﬁ  stulizing disease, and the 
need for surgery. I think it will be a tremendous step 
forward and lead to improvement in quality of life. It 
will become less common for more aggressive treat-
ment to commence only once complications occur. As 
we obtain more evidence on how to identify patients 
who are most at risk of developing some of these 
complications, we can intervene earlier and prevent 
these from occurring. So I am very optimistic. I think 
we are going to see tremendous improvements in 
treatment for these patients, particularly as we become 
more able to identify and stratify people based on their 
genetics or certain serologic evidence as to who is at 
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